Clinical

CLL’s intrinsic immune dysfunction spans humoral, cellular, and innate defects, persisting even with targeted therapy.

FDA decisions in May 2026 included 5 major oncology approvals, including first-in-class therapies for breast cancer, AML, MCL, and NMIBC.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

Men and urban minority patients with early-onset CRC face elevated CVD death risk, highlighting gaps in survivorship care and research, Meng-Han Tsai, PhD, said.

Structural racism was associated with wider NSCLC survival disparities, with a 10-point Black-White gap in highly segregated counties.

In this real-world study of patients with type 2 diabetes, treatment with semaglutide resulted in greater reductions in body weight and hemoglobin A1c than dulaglutide.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

Manufacturing questions delay review of dexmethylphenidate candidate; no safety or efficacy concerns raised.

Socioeconomic, racial, and institutional factors significantly affect treatment access and patient outcomes in Guillain-Barré syndrome, despite standardized care guidelines in the US.

Children aged 2 to 5 years with fall birthdays had higher flu vaccination rates and fewer diagnoses than those with summer birthdays.

FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms.

Phase 3 trials show bepirovirsen delivers ~20% functional cure in chronic hepatitis B in just 24 weeks.

An entirely new approach to treating one of the most intractable cancers could turn it into a chronic disease.

Early data for LINKER-AL2 show linvoseltamab drives rapid and deep responses following relapse after frontline treatment for AL amyloidosis, which has no approved therapies.

Pulmonary rehabilitation boosts respiratory strength, the 6-minute walking test, and quality of life in children despite unchanged spirometry.

DELTA 2 data show topical delgocitinib for chronic hand eczema delivers minimal systemic absorption even under maximal-use conditions.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Twice-yearly depemokimab reduced exacerbations and improved quality-of-life outcomes in type 2 asthma and CRSwNP studies.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

Systematic review finds SGLT2 inhibitors and newer CKD drugs boost QALYs and often save costs by delaying dialysis and transplant.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

New US chronic hand eczema guidance closes diagnostic gaps and spotlights emerging therapies like delgocitinib to cut itch, pain, and work disruption.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Data over 17 years from a new analysis contrast prior research in this area, but remain promising on the use of intravenous immunoglobulin in this hematologic cancer.